Clinical Trials for Neuroendocrine Tumor Grade 2

CapTemY90 for Grade 2 NET Liver Metastases

NCT ID: NCT04339036

This clinical trial is looking at a new treatment approach for patients with Grade 2 neuroendocrine tumors (NETs) that have spread to the liver. Specifically, the study is assessing how well a comb...

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

NCT ID: NCT04464122

The REBORN trial is a study looking at new ways to diagnose and monitor the treatment of neuroendocrine tumors (NENs), which are a type of cancer that can arise from hormone-producing cells. Resear...

Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial

NCT ID: NCT06855095

The ATSA Trial is a clinical study looking at how a specific treatment, called Peptide Receptor Radionuclide Therapy (PRRT), works for patients with neuroendocrine tumors, which are a type of cance...

Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases

NCT ID: NCT05987176

This clinical trial is studying the effectiveness of a treatment called 177Lu-DOTATATE compared to the best supportive care for patients who have had surgery to remove neuroendocrine tumors that ha...

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry

NCT ID: NCT06395402

This clinical trial is studying whether a personalized approach to prescribing Lutetium-177 DOTATATE (also known as Lutathera) can lead to better treatment outcomes for adults with certain types of...

Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

NCT ID: NCT06472388

This clinical trial is studying the effects of a medication called everolimus, comparing two different doses: 5 mg and 10 mg taken daily. Everolimus is used to treat patients with advanced neuroend...

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

NCT ID: NCT05111509